A Phase II Study of SSGJ-612 Plus a HER2-Targeted ADC in HR-Positive, HER2-Low or HER2-Ultralow Expression Metastatic Breast Cancer

Trial Details

NCT ID

NCT07757230

Phase

PHASE2

Sponsor

Shenyang Sunshine Pharmaceutical Co., LTD.

Status

RECRUITING

Cancer Type

HER2 Positive Breast Cancer

Interventions

• SSGJ-612 (HER2-targeted antibody)
• HER2-targeted ADC

Locations (sample)

• Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

• Voluntary participation in this study, signed informed consent form, good treatment compliance, and willingness to cooperate to complete all trial …
• Expected survival duration ≥ 3 months.
• Histopathologically confirmed breast cancer meeting all of the following criteria simultaneously:
• Metastatic tumor;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.